Shareholders in A-Mansia​

seventure logo

Seventure Partners

With over €750 million under management, Seventure Partners invests in innovative companies with high growth potential, in two main areas: life sciences and digital technologies. Seventure invests in clinical healthcare such as drugs, medical devices and diagnostics, industrial biotechnology. Seventure also invests in “beyond the pill” strategies in related fields such as digital and connected health, prevention, personalized medicine, nutrition and foodtech, with a particular interest in applications linked to the microbiome.
Innovation Industries logo

Innovation Industries

Innovation Industries is a leading Netherlands-based venture capital firm focused on agri-food tech, med tech and high-tech companies. In addition to  financial support, Innovation Industries provides operational and strategic assistance in order to optimally position portfolio companies for success. Innovation Industries has over €250 million under management and invests in companies with all growth and development stages.

Vives Inter-University Fund​

Vives Inter-University Fund

The VIVES Inter-University Fund is a multi-sector technology fund that invests in projects with significant social impact. The fund invests in spin-offs of UCLouvain or of its partner universities – KULeuven (BE), Université de Paris Diderot Descartes (FR), Wageningen Universiteit (NL), Université du Luxembourg (LU) – as well as in start-ups located within 400 kilometres from Louvain-la-Neuve. VIVES is managed by Sopartec, the technology transfer office of UCLouvain. Key portfolio companies, amongst others, include: iTeos, Novadip, Tessares, Axinesis, Botalys, Upstreem, Virovet, E-Peas, Aphea, etc.
image1

Société Régionale d’Investissement de Wallonie - SRIW

By relying on the traditional strengths of Wallonia, including excellence in research and entrepreneurial creativity, SRIW Life Sciences contributes to the development of a truly dynamic and fertile ecosystem that generates jobs, creates value and is attractive to foreign investors. From clinical development to market access, SRIW Life Sciences encourages and supports entrepreneurial initiatives capable of converting scientific innovation into products that meet medical needs. SRIW Life Sciences also supports the growth of more mature activities which already generate recurring income. The role of SRIW (Société Régionale d’Investissement de Wallonie) as a risk capital provider in the life sciences sector is crucial, considering its capital-intensive nature and the high degree of risk associated.

More information: http://www.sriw.be

view

Pierre Drion – Business Angel

For almost 20 years, Pierre Drion has been passionate about Biotech. This led him to invest in several companies and university spin-offs: Promethera, Iteos, NOvadip and A-Mansia Biotech. Prior to being a business angel, Pierre was the Partner and CEO of Petercam, former Chairman of Spadel and Unibra, Vice-Chairman of the Belgian Association of Bankers and Exchange Brokers, as well as the Director of various enterprises, namely Axa Belgium, Electrabel, Neuhaus, Luxempart. Pierre is chairman of Fondation ULB and graduated from Solvay Business School of Economics & Management.
jean christophe malrieu 3

Jean-Christophe Malrieu

For more than 25 years, J.-C. Malrieu has led multinational and local companies in the food, health and beauty sectors, including Unilever, Shiseido, Phytea, and Matis. He has extensive experience in management, marketing, sales & development and more specifically acted as CEO of Matis Cosmetics, CEO at Nutrionix, President & CEO of Phythea Food Supplements. He was the VP of export and marketing at Shiseido Group, and acted as the Regional Director Dove Asia, the International Marketing Director at Bertolli, and a Marketing Manager at several other Unilever concerns. He has joined A-Mansia as CEO since its foundation.

Patrice D. Cani

Patrice D. Cani​

Patrice D. Cani is the professor of Molecular Metabolism and Nutrition at the University of Louvain (UCLouvain), Louvain Drug Research Institute (LDRI), Brussels, Belgium. He is a researcher from the Belgian Fund for Scientific Research (FRS-FNRS). He has expertise in preclinical and clinical research in the field of cardiometabolic disorders. After a B.Sc. degree in dietetics, he joined the Faculty of Medicine of UCLouvain where he received a M.Sc. in Human Nutrition, a M.Sc. in Health Sciences, and a PhD in Biomedical Sciences (physiology, metabolism and nutrition). He is a member of the “Royal Academy of Medicine of Belgium” and has received numerous prestigious grants and scientific prizes.

With more than 290 scientific research publications, reviews and book chapters and >10 patents, he has been selected in the top 1% world-class researchers for his exceptional research performance and citations in the world since 2016. His h-index is of >100 and he is cited more than 50 000 times (Google Scholar).

Twitter:@MicrObesity and his motto is: “In Gut We Trust”.

willem de vos1

Willem M. de Vos​

Willem M. de Vos is a Distinguished Professor at the Wageningen University, Netherlands, and a Professor of Human Microbiomics at the Faculty of Medicine of the University of Helsinki, Finland. He discovered Akkermansia muciniphila and is an expert in its biology and production, the fundamental basis of A-Mansia’s prospective health supplement products. He is the leader of planning at A-Mansia, i.e., the growth and manufacturing strategy of the microbe. He is a recognized Key Opinion Leader (KOL) in the microbiome area, with >30 years of experience in academia as a professor and >25 years in industry as a consultant, scientific advisor and supervisory board member. He is also a decade-long ISI Highly Cited Scientists and has a Google Scholar h-index (academic publishing and reputational impact score) of >170, with >125,000 citations. 

Our Partners:

region wallone logo
unnamed 2
Wageningen University logo